Thromb Haemost 1991; 66(03): 329-333
DOI: 10.1055/s-0038-1646416
Review Article
Schattauer GmbH Stuttgart

125I-Fibrinogen Binding to Platelets in Myeloproliferative Disease

R Mistry
*  The Department of Pharmacology and Therapeutics, Leicester Royal Infirmary, Leicester, UK
,
M Cahil
Department of Haematology, Leicester Royal Infirmary, Leicester, UK
,
C Chapman
Department of Haematology, Leicester Royal Infirmary, Leicester, UK
,
J K Wood
Department of Haematology, Leicester Royal Infirmary, Leicester, UK
,
D B Barnett
*  The Department of Pharmacology and Therapeutics, Leicester Royal Infirmary, Leicester, UK
› Author Affiliations
Further Information

Publication History

Received 05 October 1990

Accepted 26 February 1991

Publication Date:
25 July 2018 (online)

Summary

Recent reports have suggested a variation in the density and affinity of fibrinogen binding sites in platelets from patients with myeloproliferative disorders (MPD) which may reflect platelet functional abnormalities in these subjects. We have investigated the binding of 125I-fibrinogen (125I-Fb) to gel-filtered platelets from a large relatively homogeneous group of patients with MPD compared to normal age matched controls. Twenty-two of the patients investigated had polycythaemia vera and four essential thrombocythaemia.

The maximal density and affinity (Kd) of 125I-Fb binding was assessed by saturation analysis in gel-filtered platelets (GFP) stimulated with either 10 εM ADP or 150 mU thrombin. In addition the functional significance of the binding sites was studied by evaluating the response of GFP from the two experimental groups by assessing the effects of increasing concentrations of added fibrinogen on the response to 10 εM ADP using standard light transmission aggregometry.

In both groups the density of fibrinogen binding sites expressed in response to thrombin stimulation was significantly higher (approximately 2-3 fold) than that found in response to ADP. However, fewer binding sites were detected in the MPD group as compared with the control group in response to both ADP and thrombin. The Kd for 125I-Fb was similar for both agonists in normal controls and was significantly lower than that found in the MPD subjects.

Although the 125I-Fb binding study results indicate a significant reduction in both the number and affinity of fibrinogen binding sites in patients with myeloproliferative disorders, the clinical and functional significance of these findings remain uncertain.